SCHEMBL67327

SCHEMBL67327

Cc1cn([C@@H]2O[C@H](CO)C(O)(OC(=O)OC(O)[C@@H]3O[C@H](n4cc(F)c(=O)[nH]c4=O)CC3O)C2O)c(=O)[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TK1 P04183 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65560 0.83 TK1 (0.47) TK1
SCHEMBL65561 0.82 ALDH1A1 (0.41) LMNA
SCHEMBL66481 0.80 LMNA (0.41) LMNASMN1; SMN2TK1
SCHEMBL4812752 0.75 TK1 (0.55) TK1
SCHEMBL28537470 0.73 TK1 (0.67) TK1
SCHEMBL932883 0.72 TK1 (0.45) TK1
SCHEMBL932886 0.72 TK1 (0.45) LMNATK1
SCHEMBL932884 0.72 TK1 (0.45) LMNATK1
SCHEMBL23474143 0.71 LMNA (0.65) LMNASMN1; SMN2TK1
SCHEMBL316663 0.71 TK1 (0.65) TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210139911-A1 ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY SAREPTA THERAPEUTICS, INC. 2021-05-13 US disclosed
EP-1855694-B1 ANTISENSE COMPOSITION FOR TREATING MUSCLE ATROPHY SAREPTA THERAPEUTICS INC (US) 2020-12-02 EP disclosed
US-10626396-B2 Antisense composition and method for treating muscle atrophy SAREPTA THERAPEUTICS, INC. (US) 2020-04-21 US disclosed
US-10479996-B2 Antisense antiviral compound and method for treating ss/RNA viral infection SAREPTA THERAPEUTICS, INC. (US) 2019-11-19 US disclosed
US-20180327749-A1 ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-11-15 US disclosed
US-10006031-B2 Antisense composition and method for treating muscle atrophy SAREPTA THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
US-9982261-B2 Antisense antiviral compounds and methods for treating a filovirus infection SAREPTA THERAPEUTICS, INC. (US) 2018-05-29 US disclosed
US-20170306323-A1 ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2017-10-26 US disclosed
EP-3205342-A1 ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION Sarepta Therapeutics, Inc. (US) 2017-08-16 EP disclosed
EP-2603220-B1 ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION SAREPTA THERAPEUTICS INC (US) 2017-03-15 EP disclosed
US-20060148747-A1 Antisense antiviral compound and method for treating influenza viral infection SAREPTA THERAPEUTICS, INC. 2006-07-06 US disclosed
EP-1668145-A2 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION Avi Biopharma, Inc. (US) 2006-06-14 EP disclosed
EP-1654363-A2 OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS Avi Biopharma, Inc. (US) 2006-05-10 EP disclosed
WO-2006047683-A2 ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION AVI BIOPHARMA, INC. (US) 2006-05-04 WO disclosed
WO-2006033933-A2 ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION AVI BIOPHARMA, INC. (US) 2006-03-30 WO disclosed
US-20060063150-A1 Antisense antiviral compound and method for treating ssRNA viral infection SAREPTA THERAPEUTICS, INC. 2006-03-23 US disclosed
WO-2005089247-A2 ANTISENSE COMPOSITION AND METHOD FOR TREATING CANCER AVI BIOPHARMA, INC. (US) 2005-09-29 WO disclosed
US-20050096291-A1 Oligonucleotide analog and method for treating flavivirus infections SAREPTA THERAPEUTICS, INC. 2005-05-05 US disclosed
WO-2005030800-A2 OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS AVI BIOPHARMA, INC. (US) 2005-04-07 WO disclosed
WO-2005013905-A2 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION AVI BIOPHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170306323-A1 ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION HNRNPU, MED25, SSU72 LMNA 1275/4885SMN1; SMN2 262/4885TK1 762/4885
US-10006031-B2 Antisense composition and method for treating muscle atrophy MYOF, TNNC1, MTPN LMNA 549/4885SMN1; SMN2 41/4885TK1 403/4885
US-10479996-B2 Antisense antiviral compound and method for treating ss/RNA viral infection SARS1, SSU72, RNGTT LMNA 2372/4885SMN1; SMN2 473/4885TK1 608/4885
US-10626396-B2 Antisense composition and method for treating muscle atrophy MYOF, TNNC1, MTPN LMNA 549/4885SMN1; SMN2 41/4885TK1 403/4885
US-20180327749-A1 ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY MYOF, TNNC1, MTPN LMNA 549/4885SMN1; SMN2 41/4885TK1 403/4885
US-20060148747-A1 Antisense antiviral compound and method for treating influenza viral infection RNGTT, UPF1, NSUN2 LMNA 1302/4885SMN1; SMN2 680/4885TK1 178/4885
US-20060063150-A1 Antisense antiviral compound and method for treating ssRNA viral infection SARS1, RNGTT, EIF2AK2 LMNA 1351/4885SMN1; SMN2 778/4885TK1 504/4885
US-20210139911-A1 ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY MYOF, TNNC1, MTPN LMNA 549/4885SMN1; SMN2 41/4885TK1 403/4885
US-20050096291-A1 Oligonucleotide analog and method for treating flavivirus infections NSUN2, RNGTT, ADAR LMNA 357/4885SMN1; SMN2 823/4885TK1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.